1M6MYTD1Y5YMAX
Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2025 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 603.56K | - |
| Net profit | -783.45K | - |
| EBITDA | -320.88K | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €14.21M |
Number of shares | 8.5M |
52-week high/low | €2.69 - €1.16 |
| Dividends | No |
Beta | 1.18 |
P/E ratio | -2.83 |
PEG ratio | -0.30 |
P/B ratio | 0.64 |
P/S ratio | 0.00 |
Company profile
Scandinavian Real Heart AB (Publ) entwirft und entwickelt ein künstliches Herz. Das Unternehmen entwickelt Realheart TAH zur Behandlung von Herzinsuffizienz im fortgeschrittenen Stadium. Außerdem entwickelt es RealVAD, PulsePump und Sternum-Prothesen. Das Unternehmen wurde im Jahr 2007 gegründet und hat seinen Sitz in Västerås, Schweden.
| Name | SCANDINAV. REAL HEART AB Aktie |
| CEO | Ina Laura Perkins |
| Headquarters | Västerås,
vm USA |
| Website | |
| IPO | 10/22/2019 |
| Employees | 14 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Sto | HEART.ST |
Frankfurt | 782.F |
Stockholm | HEART.ST |
Discover assets
Shareholders of SCANDINAV. REAL HEART AB Aktie also invest in the following assets
